Total tau in cerebrospinal fluid detects treatment responders among spinal muscular atrophy types 1-3 patients treated with nusinersen.

In comparison to baseline values, the results for all 30 SMA patients taken together were highly significant for all subgroups up to the 18–24 months group (Figure 2A ; Table 3 ), whereas the results for SMA type 1 subjects only, probably due to a lower number of cases analyzed, were significant for the 18–24 months group only (Figure 2B ). 3.3.

also in 132,142 other papers